It is therefore indispensable to define the dependency of tumor cells to Cdk activity in relation to the expression of pRb, p16, p21, or p27 Cdk inhibitors as well as to develop new or more specific Cdks inhibitors in order to provide alternative therapies for HCC or other cancers. The gene discussed is CDKN2A; the disease is neoplasm.